Syros Pharmaceuticals Inc (NASDAQ:SYRS) major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $7.77, for a total value of $489,510.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
SYRS opened at $7.40 on Friday. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $7.18. The firm has a market cap of $322.07 million, a PE ratio of -3.87 and a beta of 1.95. Syros Pharmaceuticals Inc has a 12 month low of $5.17 and a 12 month high of $13.16.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, May 1st. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.08. The business had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.42 million. Syros Pharmaceuticals had a negative return on equity of 74.28% and a negative net margin of 3,012.04%. As a group, sell-side analysts expect that Syros Pharmaceuticals Inc will post -1.79 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Syros Pharmaceuticals in the 1st quarter valued at approximately $48,000. Bank of America Corp DE raised its holdings in Syros Pharmaceuticals by 205.9% during the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after purchasing an additional 11,711 shares during the last quarter. Rhumbline Advisers raised its holdings in Syros Pharmaceuticals by 51.4% during the fourth quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock worth $181,000 after purchasing an additional 10,995 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its holdings in Syros Pharmaceuticals by 8.3% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock worth $369,000 after purchasing an additional 3,100 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Syros Pharmaceuticals by 8.9% during the fourth quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock worth $470,000 after purchasing an additional 6,883 shares during the last quarter. 56.16% of the stock is owned by institutional investors and hedge funds.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More: What is a blue-chip stock?
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.